Clinical trials: Functional Disorder of Gastrointestinal Tract
- Condition Functional Disorder of Gastrointestinal Tract
- Funder type Industry (pharma, biotech, devices)
Irritable Bowel Syndrome
A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal Subjects
The current study is designed to assess the safety, tolerability, pharmacokinetics (PK), gastrointestinal (GI) transit time and pharmacodynamic (PD) biomarkers of repeat oral doses of GSK3179106 administered for 14 days in normal…
- Trial name
- NCT02798991
- Testing
- GSK3179106
- Where
- Australia
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Neurogenic Bowel
An Open, Qualitative, Prospective, Multicenter Trial of a Novel Transanal Irrigation System in Spinal Cord Injured Patients.
This study is designed as an open, prospective, non-controlled, qualitative, multicentre study of a novel transanal irrigation system performed in a population of 150 subjects suffering from spinal cord injury and confirmed…
- Trial name
- NCT02979808
- Testing
- Navina Smart
- Where
- 11 sites in Denmark, France and 6 more
- Volunteers
- 150 people
- Sponsor
- Dentsply International
Type 2 Diabetes, Chronic Obstructive Pulmonary Disease
Probiotic on Type 2 Diabetes and Chronic Obstruction Pulmonary Disease
This trial is a randomized, double-blind, parallel placebo clinical trial, the purpose of which is to investigate whether the adjuvant therapy of using probiotics during the treatment of diabetic patients can decrease blood sugar…
- Trial name
- NCT05492448
- Testing
- L. salivarius AP-32 and L. reuteri GL-104, L. reuteri GL-104
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Glac Biotech Co., Ltd
Cystic Fibrosis
A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation
The purpose of this study is to evaluate the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who are homozygous for F508del, heterozygous for F508del and a gating (F/G) or residual…
- Trial name
- NCT05076149
- Testing
- VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA
- Where
- 170 sites in United States, Australia and 18 more
- Volunteers
- 597 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Irritable Bowel Syndrome With Diarrhea (IBS-D)
A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome
To evaluate the safety and tolerability, treatment effect on abdominal pain, and dose response of MD-7246 administered orally to patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
- Trial name
- NCT03931785
- Testing
- MD-7246
- Where
- 80 sites in United States
- Volunteers
- 515 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
IBD (Inflammatory Bowel Disease), IBS - Irritable Bowel Syndrome
ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects
This study is evaluating the levels of calprotectin, a protein found in stool, in healthy adults. Calprotectin is a marker of inflammation in the intestines and can help doctors tell the difference between inflammatory bowel…
- Conditions
- IBD (Inflammatory Bowel Disease), IBS - Irritable Bowel Syndrome, Crohn Disease (CD), UC - Ulcerative Colitis
- Trial name
- NCT07089420
- Testing
- ALPCO Calprotectin CLIA
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- American Laboratory Products Company
Irritable Bowel Syndrome (IBS)
qQ-lab Daily-IBS for Irritable Bowel Syndrome
Primary purpose: To assess satisfaction with overall improvement in symptoms, including individual bowel symptoms, after 4 weeks of administration of gQ-lab to patients with irritable bowel syndrome (IBS).
- Trial name
- NCT03964103
- Testing
- gQ-lab daily
- Volunteers
- 100 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Irritable Bowel Syndrome
A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females
This study will evaluate the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c. A placebo control will be utilized.
- Trial name
- NCT00547469
- Testing
- DDP733
- Where
- 69 sites in United States, Canada
- Volunteers
- 360 people
- Sponsor
- Dynogen Pharmaceuticals
Cystic Fibrosis
Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)
The purpose of the study is to evaluate the natural history of exocrine pancreatic function by assessing Fecal elastase-1 (FE-1) in infants with CF during their first year of life.
- Trial name
- NCT06506773
- Where
- 50 sites in United States, Australia and 9 more
- Volunteers
- 79 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Irritable Bowel Syndrome
Comparison of the Efficacy and Safety of Tiropramide and Octylonium in the Treatment of Irritable Bowel Syndrome
The purpose of this study was to compare the Efficacy and Safety of Tiropramide HCl and Octylonium bromide in the Treatment of Irritable Bowel Syndrome.
- Trial name
- NCT01629212
- Testing
- Tiropramide HCl 100mg, Octylonium bromide 20mg
- Where
- South Korea
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Irritable Bowel Syndrome, Relief of Irritable Bowel Syndrome Symptoms
Effects of Cultura Yoghurt in Irritable Bowel Syndrome (IBS) Patients on Intestinal and Immunological Changes
To determine the effect of cultura probiotic yoghurt on number of responders to treatment during 8 weeks of treatment in comparison to placebo.
- Conditions
- Irritable Bowel Syndrome, Relief of Irritable Bowel Syndrome Symptoms, Quality of Life
- Trial name
- NCT01127828
- Testing
- Arla Yoghurt with no probiotic, Probiotic yoghurt (Cultura)
- Where
- Sweden
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Good Food Practice, Sweden
Functional Constipation, Gastric Emptying
Effect of TU-100 on Rectal Compliance, Rectal Sensation and Small Bowel and Colonic Transit in Females With Constipation
The purpose of this study is to assess the dose-related effects of TU-100, a botanical agent that modulates gastrointestinal nerves, on rectal compliance, rectal sensation thresholds and small bowel and colonic transit in female…
- Conditions
- Functional Constipation, Gastric Emptying, Whole Gut Transit, Small Bowel Transit
- Trial name
- NCT01139216
- Testing
- Daikenchuto (TU-100)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Tsumura USA
Ileus
Study to Evaluate LB1148 for Return of Gastrointestinal Function, Decrease Post-Operative Ileus
The purpose of this study is to establish preliminary evidence of the efficacy, safety, and tolerability of LB1148 for the treatment of return of gastrointestinal function and decrease Post-Operative Ileus in subjects undergoing…
- Trial name
- NCT05056935
- Testing
- LB1148
- Where
- 6 sites in China
- Volunteers
- 131 people
- Sponsor
- Newsoara Biopharma Co., Ltd.
Irritable Bowel Syndrome (IBS)
Pilot Study to Assess the Effects of AV608 on Irritable Bowel Syndrome
The purpose of this study is to assess the effects of AV608, a neurokinin 1 (NK-1) antagonist, in subjects with Irritable Bowel Syndrome.
- Trial name
- NCT00316550
- Testing
- AV608
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Avera Pharmaceuticals
Irritable Bowel Syndrome With Constipation
Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
The purpose of this study is to determine the safety, efficacy, and dose response of a range of oral doses of linaclotide administered to patients meeting criteria for IBS-C.
- Trial name
- NCT00460811
- Testing
- Linaclotide Acetate
- Where
- 85 sites in United States, Canada
- Volunteers
- 420 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
IBS (Irritable Bowel Syndrome), Bloating
A Study Evaluating the Impact of Regular FODMAP-targeting Digestive Enzyme Blend Use on Gastrointestinal Symptoms in Individuals With Self-Reported Bloating
This study is a randomized, double-blind, placebo-controlled, within-individual crossover trial designed to assess the impact of regular use of a consumer-grade FODMAP-targeting digestive enzyme blend (FODZYME®) on…
- Conditions
- IBS (Irritable Bowel Syndrome), Bloating, Abdominal Pain, Gut Health
- Trial name
- NCT07591584
- Testing
- FODMAP-targeting digestive enzyme blend
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Kiwi Health Inc
Gastroparesis, Functional Dyspepsia
Effects of Liraglutide on Body Surface Gastric Mapping
Aim 1: To investigate, in healthy participants, the effect of liraglutide injection on gastric electrophysiology (as measured by body surface gastric mapping using the Gastric Alimetry device) during an 13-dayramping dose of…
- Conditions
- Gastroparesis, Functional Dyspepsia, Chronic Nausea and Vomiting Syndrome, Healthy
- Trial name
- NCT06500130
- Testing
- Body Surface Gastric Mapping
- Where
- New Zealand
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Alimetry
Irritable Bowel Syndrome
Efficacy and Safety of Alflorex Bei Reizdarm in Patients With Irritable Bowel Syndrome
This Post-Market Clinical-Follow Up (PMCF) study gains data on the efficacy and safety of "Alflorex bei Reizdarm", a probiotic based on Bifidobacterium longum 35624, in the daily use by irritable bowel syndrome (IBS) patients.
- Trial name
- NCT04859075
- Testing
- Bifidobacterium longum 35624
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- Medice Arzneimittel Pütter GmbH & Co KG
Irritable Bowel Syndrome
Alpha-galactosidase Enzyme and Irritable Bowel Syndrome
The purpose of this study is to determine whether alpha-galactosidase enzyme is affective in alleviating the symptoms of irritable bowel syndrome (IBS).
- Trial name
- ALFA (NCT01243853)
- Testing
- Alpha-galactosidase
- Where
- Finland
- Volunteers
- 150 people
- Sponsor
- Verman Oy Ab
Irritable Bowel Syndrome
EFESO - EFficacy Enterogermina Small Intestinal Bacterial Overgrowth
Primary objective: to assess the efficacy of Bacillus clausii versus metronidazole in the eradication of the small intestinal bacterial overgrowth, 30 days after the end of treatment.
- Trial name
- NCT00331994
- Testing
- Bacillus clausii, Metronidazole
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Sanofi